ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET ANALYSIS

Antimicrobial Susceptibility Testing Market, By Product Type (Manual Antimicrobial Susceptibility Testing Products, Automated Laboratory Instruments, and Consumables), By Application (Antibacterial, Antifungal, Anti-parasitic, and Antiviral), By Method (Disk Diffusion, Rapid Automated AST, Broth Dilution, Gradient Diffusion, and Genotypic Methods), By End User (Hospitals, Pathology/Diagnostic Laboratories, Research and Academic Institutes, Pharmaceutical and Biotechnology Companies, and Contract Research Organizations), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Feb 2025
Code : CMI2449
Pages :258
Formats :
Excel and PDF
Industry : Clinical Diagnostic

Antimicrobial Susceptibility Testing Market Size and Trends

Global antimicrobial susceptibility testing market is estimated to be valued at USD 4.21 Bn in 2025 and is expected to reach USD 6.72 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 6.9% from 2025 to 2032.

Antimicrobial Susceptibility Testing Market Key Factors

To learn more about this report, Request sample copy

The global antimicrobial susceptibility testing market is expected to grow steadily owing to the rising prevalence of hospital-acquired infections and increasing antibiotic resistance worldwide. Furthermore, the growing need to manage antimicrobial resistance and optimize antibiotic usage is expected to drive the demand for antimicrobial susceptibility testing products and services. Technological advancements in susceptibility testing platforms introducing automation and faster time-to-results will also support the market growth over the forecast period.

Increasing Product Launches by Key Market Players

Increasing adoption of inorganic growth strategies, such as product launches, by key market players is expected to drive the market growth over the forecast market. For instance, Sysmex Corporation, a medical technology company, announced that it had launched point-of-care testing system in Europe to detect antimicrobial susceptibility in just 30 minutes. The system detects the presence or absence of bacteria and assesses the effectiveness of antimicrobials using urine samples from patients suspected of having urinary tract infections (UTIs). Using a unique and proprietary microfluidic technology, the system delivers antimicrobial susceptibility testing (AST). It results in as little as 30 minutes from the start of measurement, a significant reduction compared to the several days required for conventional AST.